Question normal

The majority of US public (across the political spectrum) and both Democratic and Republican presidential candidates support the idea of allowing the Secretary of Health and Human Services to negotiate drug prices on behalf of Medicare beneficiaries. But a now dated analysis by the Congressional Budget Office suggested that this change would not materially impact drug prices.

What policy/legal changes do you think would be needed to lower Medicare drug prices in the branded and specialty pharmaceutical market? Do you believe that major policy changes are feasible given the current political environment?